Introduction
============

Acute pancreatitis (AP) is a condition characterized by sudden inflammation of the pancreas resulting from abnormal activation of digestive enzyme precursors (zymogens) within the pancreas, the most notable of which is trypsinogen. This dysregulation of digestive enzymes leads to autodigestion of the pancreas, inflammation, edema, vascular injury, and in some cases apoptotic or necrotic cell death. The severity of the disease course is determined by whether the predominant response to cellular injury is inflammation and apoptotic cell death (leading to mild, self-limiting, AP, in approximately 80% of cases) or necrotic cell death (leading to severe AP, or SAP, in approximately 20% of cases) ([@B3]). The inflammatory response involves the synthesis and secretion of inflammatory mediators, such as TNF-α, IL-1, and IL-6, by pancreatic cells and the recruitment of neutrophils to the pancreas ([@B25]). In SAP, necrosis of the pancreatic tissue occurs and nearby organs may also be affected. Patients suffer endotoxemia as a result of apical junction complex damage and intestinal barrier dysfunction ([@B2], [@B1]; [@B30]; [@B4]) and in severe cases multiple organ failure and death, with a reported mortality rate of 30% ([@B16]; [@B6]; [@B39]).

The cellular injury resulting from autodigestion of the pancreas during AP induces the accumulation of IL-17-producing CD4^+^ T helper (Th17) cells stimulating an inflammatory response that is the hallmark of this disease. In fact, a Th17/Treg imbalance is associated with various autoimmune and inflammatory diseases ([@B37]; [@B14], [@B13]; [@B18]; [@B38]). An increase in the Th17/regulatory T (Treg) cell ratio leads to considerable elevation in cytokine levels, which in turn, transduces signals via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. The SOCS (suppressor of cytokine signaling) protein family have been reported to target the JAK/STAT pathway modulating the inflammatory response ([@B11]; [@B40]). However, the interrelationships between these signaling molecules is complex with different SOCS proteins targeting different STAT regulators, which in turn affect different cytokines, thereby leading to different outcomes. It is well established in the literature that SOCS3 regulates STAT5, which is the STAT regulator for Th17 cells, and SOCS1 regulates STAT5, which is the STAT regulator for Treg cells ([@B10]; [@B20]; [@B12]; [@B42]). Furthermore, [@B43] reported that overexpression of SOCS3 inhibited the inflammatory response by suppressing JAK2/STAT3 signaling in a caerulein-induced AP model both *in vitro* and *in vivo*.

MicroRNAs (miRNAs) are protein regulators that play an important role in a wide range of cellular functions. There is increasing evidence for the close relationship between miRNA expression, Th17 cell differentiation and disease pathology ([@B8]; [@B22]; [@B45], [@B44]; [@B21]). For example, miR-384 promotes Th17 cell differentiation through targeting SOCS3, leading to the pathogenesis of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis ([@B29]). The miRNA, miR-155, which was the subject of this study, has a range of known biological functions, which include the induction of Toll-like receptor (TLR) activation in monocytes/macrophages and the modulation of TLR signaling, facilitating pro-inflammatory cellular responses ([@B32]) and initiating systemic inflammatory responses ([@B26]; [@B36]; [@B27]), as well as regulating Treg cell differentiation, maintenance, and function ([@B7]; [@B19]). The expression of this miRNA can be induced by inflammatory cytokines, such as TNFα, that are released into the circulation in the initial stages of a systemic inflammatory response ([@B26]; [@B31]) and miR-155 is considered a major inflammatory mediator that is crucial in the early stages of AP development ([@B31]; [@B17]; [@B23]; [@B34]; [@B28]). In a mouse model of SAP, [@B35] reported that miR-155 was significantly overexpressed in the intestinal epithelia, particularly during the initial inflammatory response that is characteristic of SAP ([@B31]; [@B17]; [@B23]; [@B34]; [@B28]). This TNFα-regulated miR-155 overexpression inhibited the expression of the apical junction complex component protein syntheses, ZO-1 and E-cadherin, by downregulating the post-transcriptional expression of RhoA, thereby disrupting the intestinal epithelial barrier ([@B35]).

It was proposed that expression of miR-155 induced the proliferation of Treg cells via suppression of SOCS1 ([@B19]). [@B9] confirmed this, showing that miR-155 plays an important role in promoting CD8(+) T cell immunity, and miR-155 and its target SOCS-1 are key regulators of effector CD8(+) T cells. Furthermore, miR-155 was reported to suppress the expression of SOCS1, triggering cytokine signaling through STAT5 ([@B9]). In another study, [@B41] demonstrated that miR-155 enhanced Treg and Th17 cell differentiation and Th17 cell function by targeting SOCS1. We were therefore interested in studying whether the interaction between miR-155 and SOCS1 could also play a role in the disturbed regulation of the Th17/Treg ratio in SAP. We employed a well-established mouse model of AP that involves the administration of caerulein, a cholecystokinin analogue, which at low concentration induces a mild pancreatitis that resolves within a few days, or at high concentration induces a more advanced stage of the disease resembling SAP ([@B24]). Our findings confirm the role of miR-155 as a major inflammatory mediator and offer insight into the mechanism of action of miR-155 in the disease pathology associated with SAP.

Materials and Methods {#s1}
=====================

Patients and Ethics Statement
-----------------------------

A total of 100 consecutive patients from the Shanghai Tenth People's Hospital were enrolled in this study between October 2016 and October 2017. All procedures were performed according to the guidelines of the ethical committee of Tenth People's Hospital, Tongji University, Shanghai, China, and all subjects provided informed consent to participate in the study.

All patients admitted to the hospital with a diagnosis of AP and the onset of symptoms within the last 72 h were included in this study. For each patient, the age, sex, etiological factors, body mass index (BMI), the presence/absence of organ failure and local complications, medical interventions, in-hospital mortality, and the length of hospital stay were recorded (**Table [1](#T1){ref-type="table"}**).

###### 

Differences in clinical course of mild, moderate, and severe AP.

  Characteristic           Mild AP (*n* = 40)   Moderate AP (*n* = 40)   Severe AP (*n* = 20)
  ------------------------ -------------------- ------------------------ ------------------------------
  Age                      52.42 ± 14.56        48 ± 18.15               51 ± 16.31
  **Sex**                                                                
  Male (%)                 22 (36.7%)           22 (55%)                 12 (60%)
  Female (%)               38 (63.3%)           18 (45%)                 8 (40%)
  **Etiological factor**                                                 
  Blood glucose (mmo/L)    7.81 ± 3.93          9.68 ± 5.31\*\*\*        24.48 ± 1.89\*\*\*\#\#\#
  AST (U/L)                120.55 ± 147.44      43.07 ± 20.89\*\*\*      110.85 ± 66.13\#\#\#
  LDH (U/L)                810.48 ± 467.98      745.63 ± 419.38          1626.67 ± 598.78\*\*\*\#\#\#
  WBC (10 × 10^9^/L)       11.01 ± 3.65         10.86 ± 7.46             14.91 ± 8.04\*\#
  Ca (nmol/L)              2.12 ± 0.15          2.12 ± 0.32              1.62 ± 0.55\*\#
  BUN (nmol/L)             5.35 ± 2.2           6.32 ± 3.97              10.7 ± 1.26\*\#
  FT3 (pmol/L)             2.67 ± 0.48          2.49 ± 0.49              1.83 ± 1.28\*\#
  TSH (IU/L)               0.26 ± 0.25          0.14 ± 0.15\*            0.29 ± 0.07
  FT4 (pmol/L)             12.45 ± 2.14         12.72 ± 4.55             7.8 ± 1.32\*\#
  TT3 (pmol/L)             0.74 ± 0.21          0.66 ± 0.38              0.35 ± 0.22\*\#
  TT4 (pmol/L)             78.64 ± 25.03        86.5 ± 41.82             40.5 ± 18.36\*\*\*\#\#\#

AST, glutamic oxalacetic transaminase; LDH, lactate dehydrogenase; WBC, white blood cell; Ca, Serum carbohydrate antigen 199; BUN, blood urea nitrogen; FT3, free triiodothyronine; TSH, thyrotropic hormone; FT4, free tetraiodothyronine; TT3, total triiodothyronine; TT4, total tetraiodothyronine.
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∗∗

P \< 0.01,

∗∗∗
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P \< 0.001 vs. severe AP
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The diagnosis of AP was classified into three groups retrospectively as follows: mild AP (AP, 40 patients), moderate SAP (MSAP, 40 patients), and SAP (20 patients), according to the revised Atlanta 2012 classification as we previously reported ([@B15]). Peripheral blood samples from AP patients were obtained and miR-155 expression levels in serum were detected by qRT-PCR.

Isolation and Induction of CD4^+^ T Cells
-----------------------------------------

Whole-blood samples were obtained from all of the enrolled subjects. Human PBMCs were isolated from the whole blood samples by Ficoll--Hypaque density gradient centrifugation (Solarbio, Beijing, China). After isolation, the PBMCs were washed twice and resuspended in phosphate-buffered saline (PBS) to isolate CD4^+^ T lymphocytes. The CD4^+^ T cells were then isolated from the PBMCs using a magnetic cell sorting system (MACS) (Invitrogen Dynal AS, Oslo, Norway) according to the manufacturer's instructions. The purity of CD4^+^ T lymphocytes was confirmed by fluorescence-activated cell sorting (FACS) analysis.

For Th17 differentiation, purified CD4^+^ T lymphocytes were cultured for 3 days under Th17-cell polarizing conditions: RPMI-1640 medium containing 10% fetal calf serum, 1 mM glutamine, 0.1 mM beta-mercaptoethanol, 1% non-essential amino acids

(Sigma-Aldrich, St. Louis, MO, United States), 5 ng/mL IL-2 (R&D Systems, Minneapolis, MN, United States), 20 ng/mL IL-6, 5 ng/mL transforming growth factor-b, 10 ng/mL IL-23, 2 mg/mL anti-IL-4, 2 mg/mL anti-interferon-gamma (BD Pharmingen, San Jose, CA, United States) and anti-CD3 and anti-CD28-coated beads (Invitrogen, Carlsbad, CA, United States), as previously described ([@B29]). To identify the effect of miR-155 on Th17 differentiation, miR-155 mimics were designed and synthesized by GenePharma Company (Shanghai, China) and cell transfection was performed using Lipofectamine 2000 reagent. The expression of miR-155 was detected by RT-PCR after transfection with miR-155 mimics for 48 h or miR-155 inhibitor was used to pretreat the purified CD4^+^ T lymphocytes for 24 h before the induction of Th17 polarization with/without caerulein (2 μM) induction ([@B5]).

Detection of Th17 and Treg Cell Frequencies by Flow Cytometry
-------------------------------------------------------------

Whole blood (1 mL) was diluted 1:1 with RPMI 1640 medium. The samples were stimulated with 1 μg/mL ionomycin and 25 ng/ml phorbol myristate acetate in the presence of 1.7 mg/mL monensin (all from Sigma-Aldrich) to inhibit protein transportation and then incubated for 4 h at 37°C in an atmosphere containing 5% CO~2~. Next, the samples were stained with anti-human CD4-PE-Cy5 (BD Biosciences, San Jose, CA, United States) for 15 min. Erythrocytes were lysed with lysis buffer (BD Biosciences) and removed by washing. Leukocyte cells were then permeabilized with permeabilization solution (BD Biosciences) for 10 min. The permeabilized cells were labeled with either anti-human Foxp3-FITC or IL-17-PE antibodies (BD Biosciences), and isotype-matched control antibodies were included to rule out non-specific Fc receptor binding. Finally, the samples were washed and fixed with 1.5% paraformaldehyde prior to the analyses. Three-color flow cytometry was performed and Cell Quest Pro software (BD Biosciences) was used to determine the percentages of Th1 and Th2 cells. A gate was set on the CD4^+^ T cells, and at least 5000 cells were counted. Non-specific staining with the isotype control monoclonal antibody was less than 1%.

Quantitative RT-PCR
-------------------

Total RNA from serum, CD4^+^ T cells or pancreatic tissue was extracted using Trizol reagent (Ambion, Austin, TX, United States). Quantitative RT-PCR analyses of miR-155 levels were performed using SYBRGreen miRNA assays (Genechem, Shanghai, China) with U6 small nuclear RNA as an internal reference for normalization. The relative expression levels of miRNAs were evaluated using the 2^-ΔΔct^ method and expression levels were normalized relative to those of U6. The following primers were used: miR-155, 5^′^-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACCCCTAT-3^′^ and 5^′^-ACACTCCAGCTGGGTTAATGCTAATCGTGAT-3^′^; and U6, 5^′^-CTCGCTTCGGCAGCACA-3^′^ and 5^′^-AACGCTTCACGAATTTGCGT-3^′^.

Measurement of Serum Amylase, IL-6, IL-13, and TNF-α
----------------------------------------------------

Serum amylase was detected using a commercial kit that involved a spectrophotometric method (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions. Enzyme-linked immunosorbent assay (ELISA) kits were used to evaluate the levels of TNF-α, IL-13, and IL-6 in sera.

Mouse Model of AP
-----------------

All experiments were performed in accordance with experimental protocols approved by the Committee for Research and Animal Ethics of Tenth People's Hospital, Tongji University, Shanghai, China. C57BL/6 mice, of 6--8 weeks of age, were purchased from the Model Animal Research Center of Nanjing University. The mice were housed at a constant temperature of 20--22°C with a 12 h:12 h light--dark cycle. Before the experiment, the animals were fed a standard rodent diet and allowed access to water. Twenty-four hours prior to the experiment, the mice were deprived of food but allowed access to water.

Eighty BALB/c mice were randomly divided into four experimental groups. Mice were injected via the intraperitoneal route with 0, 10, 50, or 250 μg/ml caerulein dissolved in sterile distilled water at a dose of 0.1 ml per day for 12 days; these groups modeled the control, AP, MAP, and SAP stages of disease severity. To investigate the effects of miR-155, approximately 2 × 10^7^ transforming units of recombinant lentiviruses were delivered by injection into the tail veins 7 days before caerulein induction (5 mice in each group). MiR-155 interference lentivirus vectors were constructed by Shanghai Genechem Company.

Mice were euthanized under anesthesia (10% chloral hydrate, 3 ml/kg body weight) by intraperitoneal injection 24 h after the injection of sodium deoxycholate, and tissue samples were collected immediately. Arterial blood samples were collected from the abdominal aorta.

Histological Analyses
---------------------

For histological analyses, pancreatic tissue from each group was fixed with 4% paraformaldehyde, then embedded in paraffin. Sections (4-μm thick) that had been deparaffinized and rehydrated were stained with hematoxylin and eosin (H&E).

Luciferase Reporter Assay
-------------------------

To investigate whether miR-155 directly regulates SOCS1 expression, the sequence of the 3^′^-untranslated region (UTR) of SOCS1 was inserted downstream of a Renilla luciferase open reading frame in the pGL3-CMV vector (Promega, Madison, WI, United States). HEK293T cells were transfected with the pGL3-basic construct along with either the miR-155 mimic or a scrambled control using Lipofectamine 2000 (Invitrogen). After 24 h, the cells were harvested, and luciferase activity was measured. The results are presented as the ratio of Renilla luciferase activity to firefly luciferase activity. All of these experiments were performed at Yingbai Corporation (Shanghai, China).

Western Blot Analysis
---------------------

Western blotting was performed as previously described ([@B33]). After non-specific binding was blocked, the membranes were incubated with primary antibodies against SOCS1, IL-17, STAT1, pSTAT1 or GAPDH (1:1000) (Sigma--Aldrich, St. Louis, MO, United States). Immunoreactive proteins were visualized using enhanced chemiluminescence detection (Bioworld Technology, Nanjing, China). Immunoreactive labeling was analyzed using ImageJ 1.44 software and normalized to GAPDH protein levels.

Statistical Analysis
--------------------

Statistical analysis was carried out using the SPSS software package (version 17; IBM Corporation, Armonk, NY, United States). All of the descriptive variables were expressed as the mean ± SD. Comparisons between two groups were performed using the Student's *t*-test, and comparisons between more than two groups employed Tukey's multiple comparisons test. *P* \< 0.05 was considered significant.

Results
=======

MiR-155 Regulates AP Pathogenesis
---------------------------------

The diagnoses of the patients enrolled in this study were classified into three groups retrospectively: mild (AP), moderate (MAP), and severe (SAP), according to the revised Atlanta 2012 classification. To determine whether miR-155 expression levels differed with disease severity, quantitative RT-PCR analyses of miR-155 expression in the serum of patients diagnosed with AP were performed. As shown in **Figure [1A](#F1){ref-type="fig"}**, miR-155 expression levels positively correlated with disease severity, with the SAP group of patients displaying the highest miR-155 expression.

![MiR-155 regulates AP pathogenesis. **(A)** Quantitative RT-PCR analyses of miR-155 expression in the sera of AP patients. Data are presented as the mean ± SD. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001. **(B)** Western blot analysis of SOCS1 expression in CD4^+^ T cells isolated from the different groups of AP patients. GAPDH was detected as an endogenous control. **(C)** The relative SOCS1 expression was determined by densitometric analysis. Data are presented as the mean ± SD. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 vs. AP group. ^\#\#\#^*P* \< 0.001 vs. MAP group. **(D--F)** ELISA to determine the concentrations of inflammatory factors IL-6, IL-13 and TNF-α in the sera from the different groups of AP patients. Data are presented as the mean ± SD. ^∗^*P* \< 0.05, ^∗∗∗^*P* \< 0.001 vs. AP group. ^\#\#^*P* \< 0.01 vs. MAP group. **(G)** Representative flow cytometric analyses of IL-17 and Foxp3 cells among CD4^+^ gated cells from different groups of AP patients. **(H)** The percentage of IL-17^+^ cells. Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. AP group. ^\#\#\#^*P* \< 0.01 vs. MAP group. AP, mild AP; MAP, moderate AP; SAP, severe AP.](fphys-09-00686-g001){#F1}

SOCS1 has previously been reported to be a target for suppression by miR-155 ([@B19]). We therefore analyzed SOCS1 expression in the CD4^+^ T lymphocytes isolated and purified from the whole blood of AP patients by western blot analysis (**Figure [1B](#F1){ref-type="fig"}**). The relative SOCS1 expression decreased with increased disease severity, with the SAP group of patients displaying the lowest levels of SOCS1 expression (*P* \< 0.001 vs. AP group, *P* \< 0.001 vs. MAP group).

SOCS1 suppresses cytokine signaling via modulation of the STAT pathway ([@B11]; [@B40]). We therefore performed ELISA on the sera from the three groups of AP patients to determine the concentrations of inflammatory factors IL-6, IL-13 and TNF-α (**Figures [1D](#F1){ref-type="fig"}--[F](#F1){ref-type="fig"}**). The results showed a clear increase in all three inflammatory factors analyzed corresponding to disease severity, with the sera from patients diagnosed with SAP exhibiting the highest levels of IL-6, IL-13, and TNF-α (*P* \< 0.001 vs. AP group, *P* \< 0.01 vs. MAP group).

The accumulation of IL-17-producing CD4^+^ T helper (Th17) cells has been linked to AP pathogenesis, and is thought to significantly contribute to the inflammatory response. We next investigated the Th17/Treg ratio in the AP patients by flow cytometric analyses of CD4^+^ gated cells isolated from the whole blood of the different groups of AP patients using antibodies against IL-17 and Foxp3 (**Figure [1G](#F1){ref-type="fig"}**). Foxp3 is a specific marker of CD4^+^ regulatory T cells, and an IL-17 antibody was used to detect Th17 cells. Our results demonstrated that the percentage of IL-17^+^ cells was significantly increased with increasing disease severity, indicating an elevated Th17/Treg ratio (**Figure [1H](#F1){ref-type="fig"}**). The patients diagnosed with SAP exhibited the highest percentage of IL-17^+^ cells (*P* \< 0.001 vs. AP group, *P* \< 0.01 vs. MAP group).

Taken together, these findings indicate that miR-155 expression levels positively correlate with AP disease severity and expression of the miR-155 target, SOCS1, negatively correlates with AP pathogenesis. The severity of AP, and the corresponding downregulation of SOCS1, related to an increase in the concentration of inflammatory factors IL-6, IL-13 and TNF-α, and the percentage of IL-17^+^ cells.

MiR-155 Promotes the Generation of Th17 Cells
---------------------------------------------

To analyze the role of miR-155 in the accumulation of IL-17^+^ cells, CD4^+^ T cells isolated from AP patients were pretreated with miR-155 mimics or miR-155 inhibitor for 24 h prior to analysis. Then, following 3 days of induction under Th17-polarizing conditions, flow cytometric analyses were performed on these CD4^+^ T cells (**Figure [2A](#F2){ref-type="fig"}**). The percentage of IL-17^+^ cells was significantly increased in those cells in which miR-155 was overexpressed and decreased in cells in which miR-155 was inhibited compared with the control (*P* \< 0.001; **Figure [2B](#F2){ref-type="fig"}**), indicating that miR-155 promotes the generation of Th17 cells.

![MiR-155 promotes the generation of Th17 cells. CD4^+^ T cells from AP patients were first pretreated with miR-155 mimics or miR-155 inhibitor for 24 h. **(A)** Flow cytometric analyses of CD4^+^ T cells after 3 days of induction under Th17-polarizing conditions. **(B)** The percentage of IL-17^+^ cells. Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. control. ^\#\#\#^*P* \< 0.01 vs. miR-155 overexpression group. **(C)** ELISA to detect IL-17 in the culture supernatants of the pretreated CD4^+^ T cells (*n* = 5 per group). Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. control. ^\#\#\#^*P* \< 0.01 vs. miR-155 overexpression group. **(D)** Western blot analysis of SOCS1 expression in the pretreated CD4^+^ T cells (*n* = 3). GAPDH was detected as an endogenous control. **(E)** The relative SOCS1 expression was determined by densitometric analysis. Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. control. ^\#\#\#^*P* \< 0.01 vs. miR-155 overexpression group.](fphys-09-00686-g002){#F2}

To determine the levels of IL-17 production in response to miR-155 overexpression, ELISA of IL-17 was performed on the culture supernatants of the pretreated CD4^+^ T cells from AP patients (**Figure [2C](#F2){ref-type="fig"}**). MiR-155 overexpression upregulated IL-17 levels in the cell supernatants (*P* \< 0.001 vs. control), and pretreatment with the miR-155 inhibitor reversed this trend (*P* \< 0.001 vs. control, *P* \< 0.01 vs. miR-155 overexpression group).

Next, we investigated SOCS1 expression by western blot analysis of CD4^+^ T cells isolated from the AP patients (**Figure [2D](#F2){ref-type="fig"}**). SOCS1 protein expression was significantly decreased in miR-155 overexpressing cells (*P* \< 0.001 vs. control), and this trend was not only reversed following pretreatment with the miR-155 inhibitor but SOCS1 protein expression was significantly increased compared with the control (*P* \< 0.001 vs. control, *P* \< 0.01 vs. miR-155 overexpression group; **Figure [2E](#F2){ref-type="fig"}**). This not only provided further evidence of the suppression of SOCS1 by miR-155 and the resulting upregulation of the inflammatory response, but also indicated that inhibition of miR-155 not only restored SOCS1 levels but positively upregulated SOCS1 expression.

Inhibition of miR-155 Expression Decreased the Conversion of CD4^+^ T Cells to Th17 Cells After Caerulein Induction
-------------------------------------------------------------------------------------------------------------------

Caerulein induction is a well-established method of stimulating the pathology of AP. To investigate the role of miR-155 in modulating Th17 cells, CD4^+^ T cells were pretreated with caerulein (2 μM) for 48 h following treatment with the miR-155 inhibitor, then flow cytometric analyses were performed (**Figure [3A](#F3){ref-type="fig"}**). The percentage of IL-17^+^ cells was significantly decreased in the AP-induced cells treated with the inhibitor (*P* \< 0.001 vs. control; **Figure [3B](#F3){ref-type="fig"}**), further confirming the role of miR-155 in modulating the Th17 ratio. ELISA to detect IL-17 expression levels in the culture supernatants revealed downregulation of IL-17 in the absence of miR-155 in AP-induced cells (*P* \< 0.001 vs. control; **Figure [3C](#F3){ref-type="fig"}**). Furthermore, western blot analysis demonstrated significantly increased SOCS1 expression in AP-induced cells following treatment with the inhibitor (*P* \< 0.001 vs. control; **Figures [3D](#F3){ref-type="fig"},[E](#F3){ref-type="fig"}**). Taken together, these findings confirmed that inhibition of miR-155 expression decreased the conversion of CD4^+^ T cells to Th17 cells after caerulein induction, thereby decreasing IL-17 production, with a simultaneous increase in SOCS1 expression.

![Inhibition of miR-155 expression decreased the conversion of CD4^+^ T cells to Th17 cells following caerulein induction. CD4^+^ T cells were first induced with caerulein (2 μM) to simulate AP for 48 h and were pretreated with or without miR-155 inhibitor. **(A)** Flow cytometric analyses of IL-17 cells (*n* = 3). **(B)** The percentage of IL-17^+^ cells. Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. control. **(C)** ELISA of IL-17 in the culture supernatants (*n* = 5 per group). Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. control. **(D)** Western blot analysis of the expression of SOCS1 in the pretreated CD4^+^ T cells (*n* = 3). GAPDH was detected as an endogenous control. **(E)** The relative SOCS1 expression was determined by densitometric analysis. Data are presented as the mean ± SD. ^∗∗∗^*P* \< 0.001 vs. control.](fphys-09-00686-g003){#F3}

SOCS1 Is a Direct Target of miR-155
-----------------------------------

To investigate the potential target genes of miR-155, bioinformatic analysis was performed using the TargetScan software. Using this approach, an miR-155 binding site was predicted in the 3^′^-UTR of SOCS1 mRNA (**Figure [4A](#F4){ref-type="fig"}**). To examine the regulation of SOCS1 by miR-155, we performed a dual-luciferase reporter assay in CD4^+^ T cells. Cells were co-transfected with wild-type (WT) or mutant (MUT) SOCS1 3^′^-UTR plasmids, and miR-155 or control miR. MiR-155 significantly inhibited the luciferase reporter activity of the WT (*P* \< 0.001 vs. control group) but not the MUT SOCS1 3^′^-UTR, indicating that SOCS1 is a direct target of miR-155 (**Figure [4B](#F4){ref-type="fig"}**). RT-PCR analysis of SOCS1 in miR-155-transfected cells confirmed that this miRNA downregulated the expression of SOCS1 in CD4^+^ T cells (*P* \< 0.001 vs. control, **Figure [4C](#F4){ref-type="fig"}**). This effect was reversed by treatment of the cells with miR-155 inhibitor (*P* \< 0.001 vs. control, *P* \< 0.001 vs. miR-155 group; **Figure [4C](#F4){ref-type="fig"}**).

![SOCS1 is a direct target of miR-155. **(A)** Illustration of the sequence match between miR-155 and SOCS1 mRNA determined using TargetScan. **(B)** Luciferase activity of reporter vectors containing wild-type (WT) or mutated (MUT) SOCS1 3^′^-UTR co-transfected with miR-155 or control miR (ctrl; *n* = 3 per group). Data are presented as means ± SD. ^∗∗∗^*P* \< 0.001 vs. control group. **(C)** Rt-PCR analyses for SOCS1 in CD4^+^ T cells 3 days post-transfection (*n* = 3 per group). Data are presented as means ± SD. ^∗∗∗^*P* \< 0.001 vs. control group. ^\#\#\#^*P* \< 0.001 vs. miR-155 group.](fphys-09-00686-g004){#F4}

The Effect of miR-155 on Histological Changes in the Pancreas
-------------------------------------------------------------

To examine the effects of miR-155 on inflammatory cytokine expression in the pancreatic tissue of mice, the animals were injected with miR-155 interference lentiviruses followed by 10, 50, or 250 μg/ml caerulein to model the AP, MAP and SAP stages of disease severity. ELISA revealed that in the miR-155-silenced pancreatic tissue the production of inflammatory cytokines, IL-6 (**Figure [5A](#F5){ref-type="fig"}**), TNF-α (**Figure [5B](#F5){ref-type="fig"}**) and IL-13 (**Figure [5C](#F5){ref-type="fig"}**), was decreased compared with those injected with the control lentiviruses. This effect became more pronounced as the disease stage progressed. Similarly, HE staining of the pancreatic tissue from the different disease stages in the mice injected with control lentiviruses revealed slight interstitial edema and low levels of inflammatory cell infiltration in the AP mice progressing to broad necrosis of acinar cells and interstitial edema in SAP mice (**Figure [5D](#F5){ref-type="fig"}**). Whereas in the mice injected with miR-155 interference lentiviruses, the pathogenic condition was attenuated at all disease stages revealing an improvement in the pathology of the pancreas compared with the control. Western blot analysis confirmed downregulation of SOCS1, IL-17, and pSTAT1 in response to miR-155 silencing compared with control mice throughout the course of the disease (**Figure [5E](#F5){ref-type="fig"}**). These findings clearly indicated that miR-155 plays a crucial role in the progression of AP disease via a mechanism that involves the induction of an inflammatory response, regulation of the Th17/Treg ratio, and targeting of SOCS1 via activation of the STAT signaling pathway.

![The effect of miR-155 on histological changes in the pancreas. BALB/c mice were injected with miR-155 interference lentiviruses (anti-miR-155) or control lentiviruses (anti-ctrl) followed by 10, 50 or 250 μg/ml caerulein to model the AP, MAP and SAP stages of disease severity. **(A--C)** The expression of inflammatory factors IL-6 **(A)**, TNF-α **(B)** and IL-13 **(C)** was measured by ELISA (*n* = 5). Data are presented as the mean ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 vs. anti-ctrl group. **(D)** HE staining of the pancreatic tissue. **(E)** Western blot analysis of the expression levels of SOCS1, IL-17, STAT1, and pSTAT1 (*n* = 3). GAPDH was detected as an endogenous control.](fphys-09-00686-g005){#F5}

Discussion
==========

SAP is a serious, often lethal, condition associated with intestinal barrier dysfunction resulting from apical junction complex damage. This cellular injury is caused by the dysregulation of digestive enzymes leading to autodigestion of the pancreas, which in turn leads to the accumulation of Th17 cells and the induction of a significant inflammatory response, which is a hallmark of SAP. The interaction between miR-155 and SOCS1 has previously been reported, as has the resulting perturbation of differentiated T cell populations. However, this remained to be experimentally demonstrated in SAP. Here, we performed *in vitro* assays using CD4^+^ T cells isolated from AP patients and *in vivo* assays using a mouse model of caerulein-induced AP, to analyze the mechanism by which the upregulation of miR-155 contributes to SAP. Our findings confirmed that miR-155 mediated upregulation of the Th17/Treg ratio and inflammatory cytokine expression levels via the suppression of SOCS1 in experimental AP.

In this study, SOCS1 was identified as one of the target genes of miR-155, confirming the findings of a previous report ([@B19]). Further to this, we provided evidence that miR-155 binds directly to the 3^′^-UTR of SOCS1. Our findings clearly indicated that miR-155 expression and the inflammatory response correlate positively with the severity of AP, while they correlate negatively with the levels of SOCS1. This was in line with previous findings for miR-155 in other inflammatory disease or animal models ([@B9]; [@B32]). For example, [@B9] reported that miR-155 and its target SOCS1 were key regulators of effector CD8(+) T cells, thereby affecting cytokine signaling through STAT5. Similarly, [@B32] previously demonstrated the role for miR-155 in facilitating pro-inflammatory cellular responses during experimental colitis in mice by reducing Th1/Th17 responses.

In the current study, in addition to showing that miR-155 overexpression dysregulated *SOCS1* gene expression at the post-transcriptional level, interestingly, we also showed that miR-155 inhibition not only restored SOCS1 protein expression but actually upregulated its expression. This suggested that miR-155 may compete with another regulatory factor that positively affects SOCS1 expression, although further studies will be required to confirm this. Investigations will also be needed to analyze the potential clinical implications of upregulated SOCS1 expression in the absence of miR-155 if this microRNA is to be targeted therapeutically.

The SOCS family of proteins are cytokine-inducible negative regulators of cytokine signaling that operate by a negative feedback mechanism. The SOCS proteins are reported to modulate cytokine signaling via the JAK/STAT pathway ([@B11]; [@B40]). The interactions between SOCS proteins and STAT regulators is complex, with different SOCS proteins modulating cytokine signaling via different STAT regulators. The role of SOCS3 in mediating the inflammatory response during SAP has previously been reported ([@B43]). In our study, the suppression of SOCS1 by miR-155 during the initial stages of SAP was found to lead to upregulation of the Th17/Treg ratio and inflammatory cytokine expression levels via a mechanism involving the JAK/STAT pathway, in line with previous findings ([@B32]; [@B29]). These results were expected since Th17 cell accumulation and upregulation of pro-inflammatory cytokines in the pancreas are well recognized features of AP pathogenesis. However, only Th17 cell numbers were assessed in this study, future studies will be needed to measure Treg cell numbers and confirm any alterations since it has been suggested in the literature that SOCS1 inhibition upregulates Treg cells.

Limited treatment modalities are currently available for SAP. Identification of a therapeutic strategy to limit local inflammation and prevent its progression to severe disease is therefore crucial to limit the mortality associated with pancreatitis. The role of miRNAs in disease pathogenesis is a rapidly expanding field of research and a promising potential source of new therapeutic targets. Our findings provide strong evidence that miR-155 is increased in AP patients, and its concentration increases with disease severity. Furthermore, inhibition of miR-155 in a mouse model of AP led to better disease outcomes. To our knowledge, this is the first study to demonstrate that the interaction between miR-155 and SOCS1 plays a role in the disturbed regulation of the Th17/Treg ratio in SAP and demonstrates that this microRNA is therefore a promising candidate biomarker and/or therapeutic target for the treatment of SAP.
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